Sagimet Biosciences Inc. (SGMT)
Automate Your Wheel Strategy on SGMT
With Tiblio's Option Bot, you can configure your own wheel strategy including SGMT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SGMT
- Rev/Share 0.0
- Book/Share 4.0428
- PB 1.8749
- Debt/Equity 0.0012
- CurrentRatio 17.5515
- ROIC -0.5133
- MktCap 234988406.0
- FreeCF/Share -1.6844
- PFCF -4.3332
- PE -4.1097
- Debt/Assets 0.0011
- DivYield 0
- ROE -0.3988
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SGMT | Wedbush | -- | Outperform | -- | $28 | Aug. 11, 2025 |
| Resumed | SGMT | H.C. Wainwright | -- | Buy | -- | $29 | Aug. 7, 2025 |
| Initiation | SGMT | Canaccord Genuity | -- | Buy | -- | $28 | July 24, 2025 |
| Initiation | SGMT | Oppenheimer | -- | Outperform | -- | $30 | Dec. 6, 2024 |
News
All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Sagimet Biosciences Inc. (SGMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts
Published: October 07, 2025 by: Seeking Alpha
Sentiment: Positive
Sagimet Biosciences (SGMT) is well-positioned financially, with $135 million in cash and minimal debt, supporting operations through early 2028. SGMT's lead asset, denifanstat, is advancing in combination studies with resmetirom for MASH, with key data expected by early 2026. The FDA's acceptance of noninvasive endpoints like FibroScan could accelerate SGMT's trial timelines and reduce development complexity.
Read More
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was generally well tolerated Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, for development in acne SAN MATEO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported that data from a Phase 3 clinical trial for the treatment of moderate to severe acne vulgaris conducted by Sagimet's license partner Ascletis Bioscience Co. Ltd.
Read More
Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development
Published: August 29, 2025 by: Seeking Alpha
Sentiment: Positive
Sagimet Biosciences offers a unique play in MASH with Denifanstat, a FASN inhibitor showing both fat reduction and fibrosis regression in Phase 2b. The FDA's acceptance of non-invasive trial endpoints accelerates Sagimet's Phase 3 timeline, lowering barriers and costs for approval. Despite recent gains, Sagimet's valuation remains attractive, supported by a strong cash position and significant market opportunity if Phase 3 succeeds.
Read More
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 437.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567
Published: June 04, 2025 by: Seeking Alpha
Sentiment: Positive
Sagimet Biosciences' partner Ascletis reported strong phase 3 results for denifanstat in moderate-to-severe acne, validating FASN inhibition as a novel oral treatment. Sagimet is advancing next-gen FASN inhibitor TVB-3567 for U.S. acne trials and planning a phase 1b combo study with denifanstat and resmetirom for MASH. The acne market is large and underserved, while FASN inhibition offers potential in both dermatology and metabolic disease, expanding SGMT's addressable market.
Read More
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN MATEO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Thursday, May 29, 2025 at 1:00 PM ET.
Read More
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026
Read More
About Sagimet Biosciences Inc. (SGMT)
- IPO Date 2023-07-17
- Website https://sagimet.com
- Industry Biotechnology
- CEO David A. Happel
- Employees 14